^
Association details:
| Biomarker: | DLL3 underexpression |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Rova-T (rovalpituzumab tesirine) (DNA replication inhibitor, DLL3-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract LB-136: Pediatric Preclinical Testing Consortium evaluation of a DLL3-targeted antibody drug conjugate rovalpituzumab tesirine, in neuroblastoma
Excerpt:
DLL3 protein was expressed in 27 of 32 NB PDXs….Among the PDXs tested, DLL3 expression was lowest in COG-N-452x; this model showed superior in vivo sensitivity to Rova-T compared with the other 2 models which had higher DLL3 expression and also higher IC50 values for PBD.
DOI:
https://doi.org/10.1158/1538-7445.AM2018-LB-136
